A5000320395- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Transplantation: Methods and Outcomes
- Pulmonary Hypertension Research and Treatments
- Dialysis and Renal Disease Management
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Renal Transplantation Outcomes and Treatments
- Cardiac pacing and defibrillation studies
- Climate Change and Health Impacts
- Mechanical Circulatory Support Devices
- Organ Transplantation Techniques and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Congenital Heart Disease Studies
- Diabetes Treatment and Management
- Vascular Procedures and Complications
- Lymphoma Diagnosis and Treatment
- Cardiac Fibrosis and Remodeling
- Lung Cancer Diagnosis and Treatment
- Organ Donation and Transplantation
- RNA modifications and cancer
Azienda USL di Bologna
2022-2023
Hospital Universitari Germans Trias i Pujol
2020-2022
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2017-2022
Universitat de Barcelona
2019-2022
Hospital Clínic de Barcelona
2017-2021
Universitat Autònoma de Barcelona
2021
Centro de Investigación en Red en Enfermedades Cardiovasculares
2021
European Institute of Oncology
2005-2019
University of Leeds
2019
Leeds Teaching Hospitals NHS Trust
2019
The nonculprit lesion (NCL) management in ST-segment-elevation myocardial infarction patients with multivessel disease is debated. We sought to assess whether quantitative flow ratio (QFR), a noninvasive tool identify potentially flow-limiting lesions, may be reliable this scenario.The present proof-of-concept study based on 3-step process: (1) identification of the QFR reproducibility NCLs assessment (cohort A, n=31); (2) prospective validation diagnostic accuracy respect fractional reserve...
Abstract Aims Prior studies have not fully characterized the haemodynamic effects of angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF–PH). The aim Treatment PH With Angiotensin II Receptor Blocker Neprilysin Inhibitor HFpEF Patients CardioMEMS Device (ARNIMEMS‐HFpEF) study is to assess artery pressure (PAP) dynamics by means implanted PAP monitors patients HFpEF–PH treated...
Abstract The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism action unclear. Here we aimed artificial intelligence (AI) characterize empagliflozin HFpEF at molecular level. We retrieved information regarding pathophysiological motifs and differentially expressed genes/proteins, together target bioflags, from specialized publicly available databases....
Abstract Purpose Wire-based coronary physiology pullback performed before percutaneous intervention (PCI) discriminates artery disease (CAD) distribution and extent, is able to predict functional PCI result. No research investigated if quantitative flow ratio (QFR)–based assessment provide similar information. Methods In 111 patients (120 vessels) treated with PCI, QFR was measured both after PCI. Pre-PCI trace used discriminate patterns of CAD (focal, serial lesions, diffuse disease,...
Abstract To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients different etiologies with depressed preserved LVEF. A total 2368 consecutive patients (mean age 66.4 ± 12.9 years, 71% men, 15.4% LVEF) admitted clinic August September were included the study. Patients divided into five quintiles (Q) according period admission. Trends for all-cause cardiovascular Q1 Q5 assessed by linear regression. LVEF < 50% had progressive decrease rates...
Abstract Aims In ambulatory patients with chronic heart failure (HF), congestion and decongestion assessment may be challenging. The aim of this study is to assess the value lung ultrasound (LUS) in outpatients HF characterizing decompensation recompensation, outcomes prediction. Methods results Heart attended establish were included. LUS was blindly performed at baseline (LUS1) clinical recompensation (LUS2). B‐lines counted eight scanned areas. Diagnosis no vs. right‐sided, left‐sided, or...
<i>Background:</i> Bladder cancer is the fifth most common among men and seventh women. At diagnosis, at least 25% of bladder tumors are locally or systemically advanced. Systemic chemotherapy only current modality for advanced metastatic transitional cell carcinoma bladder. Recently, a phase III randomized study has demonstrated that regimen with gemcitabine (GMC) cisplatin (CDDP) had survival advantage similar to standard M-VAC (methotrexate, vinblastine, doxorubicin...
We assessed differences in long-term all-cause and cardiovascular (CV) mortality heart failure (HF) outpatients based on the etiology of HF. Consecutive patients admitted to HF Clinic from August 2001 September 2019 (N = 2587) were considered for inclusion. was divided into ischemic disease (IHD), dilated cardiomyopathy (DCM), hypertensive disease, alcoholic cardiomyopathy, drug-induced (DICM), valvular hypertrophic cardiomyopathy. All-cause death CV primary end points. Among 2387 included...
Background Nuisance bleeding is a major determinant of quality life and drug discontinuation in patients on dual antiplatelet therapy (DAPT). However, no randomized trial has been focused the impact nuisance life. Methods BATMAN an investigator-driven, randomized, controlled, single-center, open (NCT02554006). Four hundred forty-eight consecutive with indication to at least 6 months DAPT were to: i) multimodal counseling program bleedings (interventional arm); ii) usual discharge process...
Abstract Heart failure (HF) is a major public health problem and leading cause of hospitalization in western countries. Over the past decades, goal has been to find best method for monitoring congestive symptoms prevent hospitalizations. Addressing this task through regular physician visits, blood tests, imaging proven insufficient optimal control not decreased enough HF-related rates. In recent years, new devices have developed reason CardioMEMS one therapeutic options. shown be effective...
Background:No study has evaluated the clinical consequences of stent fracture (SF) detected during index percutaneous coronary intervention (PCI). Thus, we sought to investigate relationship between SF PCI and outcome.
e13017 Background: F16-IL2 is a recombinant fusion protein composed of the antibody fragment scFv(F16) (specific to alternatively spliced domain A1 tenascin-C) and human interleukin-2 (IL-2). Extensive preclinical studies have shown that F16- IL2 capable selectively efficiently localizing in tumor stroma vivo. Furthermore, strongly potentiates therapeutic action many anticancer agents. We been performing two phase Ib evaluate safety, tolerability, recommended dose (RD), early signs activity...